AACR 2026 – Matisse paints a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
ASCO 2026 preview – Revolution completes its rout
Daraxonrasib scores a plenary session late-breaker.
Gilead edges further away from Arcus
The disclosure comes as another of Arcus's TIGIT trials flops.
AACR 2026 – Circle’s focus narrows
First-in-human results prompt a biomarker-defined approach for CID-078.
AACR 2026 – a CCR8 reality check
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
AACR 2026 – Qilu challenges Torl in Claudin6
The company’s conjugate QLS5132 has produced intriguing, but early results.
Allogene finds a way forward for allogeneic Car-T
After setbacks, cema-cel might have a path to approval in lymphoma.
